<p>马里兰州盖瑟斯堡 --（Newsfile Corp. -2026 年 3 月 26 日）- Shuttle Pharmaceuticals Holdings, Inc.（纳斯达克：SHPH）（&#34;Shuttle Pharma&#34;或&#34;公司&#34;）今天宣布其_molecule.ai_平台的重大进展，显著扩展了其在治疗发现方面的能力，并将公司置于基于人工智能的药物开发的前沿。</p>
<p>最新发布引入了新的模型，使用户能够更有效地评估、优先排序和推进治疗候选药物。通过将增强的预测和生成能力整合到一个统一的平台中，Shuttle Pharma 正在加速从碎片化数据分析向可扩展的端到端治疗开发解决方案的过渡。</p>
<p>此次更新标志着基于人工智能的药物发现的关键演变：从独立模型输出到更复杂的推理系统。该平台现在可以识别和优先考虑基因与疾病通路之间的关系，并预测化合物与特定生物靶点的相互作用。结合现有的分子预测工具，molecule.ai 提供了一个更连贯和高效的框架，用于评估治疗机会，从而在发现生命周期的早期推动更快速、更高信心的决策。</p>
<p>此外，公司还展示了其下一代自主人工智能代理系统的预览，该系统建立在前沿人工智能模型之上。该系统旨在超越传统的单步预测，通过在复杂科学工作流程中实现多步推理和多代理协调。代理将能够摄取多模态数据，利用集成工具，并执行离散的研究任务，显著减少人工工作量并提高研究团队的产出。</p>
<p>&#34;此次发布代表了朝着完全自主治疗发现迈出的重要一步，&#34; Shuttle Pharma 首席执行官 Chris Cooper 表示。&#34;我们不仅在提高模型性能，我们正在重新定义药物开发工作流程的执行方式。通过将推理、预测和自动化整合到一个平台中，molecule.ai 有潜力显著缩短时间表、降低成本，并提高开发管道的成功概率。我们相信这使 Shuttle Pharma 能够在下一代基于人工智能的生物制药创新中发挥领导作用。&#34;</p>
<p>随着 Shuttle Pharma 继续扩展 molecule.ai 的能力，公司仍然专注于构建一个可扩展的平台，以解锁新的治疗机会，提高开发效率，并为股东创造长期价值。</p>
<p><strong>关于 Shuttle Pharma</strong></p>
<p>Shuttle Pharmaceuticals Holdings, Inc.（纳斯达克：SHPH）拥有一个用于分子发现和早期药物开发的药物软件人工智能（&#34;AI&#34;）驱动平台。通过将现代人工智能技术与结构化科学工作流程相结合，Molecule.ai 平台帮助研究人员更高效地探索化学空间，以更清晰的视角评估分子想法，并在药物开发的最早阶段做出更明智的决策。</p>
<p><strong>关于前瞻性声明的警示说明</strong></p>
<p>本新闻稿中关于未来期望、计划和前景的声明，以及关于非历史事实事项的任何其他声明，可能构成&#34;前瞻性声明&#34;。这些声明包括但不限于关于 Molecule.ai 平台的发展和未来能力的声明。&#34;预期&#34;、&#34;相信&#34;、&#34;继续&#34;、&#34;可能&#34;、&#34;估计&#34;、&#34;期望&#34;、&#34;打算&#34;、&#34;可能&#34;、&#34;计划&#34;、&#34;潜在&#34;、&#34;预测&#34;、&#34;项目&#34;、&#34;应该&#34;、&#34;目标&#34;、&#34;将&#34;、&#34;会&#34;及类似表达旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果有实质性差异，包括我们实现 Molecule.ai 平台预期收益的能力、与未来客户的获取和保留相关的风险、我们产生收入的能力、我们资助未来运营的能力、与我们的知识产权相关的风险、我们维持普通股在纳斯达克上市的能力的风险，以及 Shuttle Pharma 在 SEC 备案中讨论的其他因素。本新闻稿中包含的任何前瞻性声明仅在本日期有效，除非联邦证券法要求，否则 Shuttle Pharma 不承担更新任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。</p>
<p><strong>Shuttle Pharmaceuticals</strong></p>
<p>Chris Cooper</p>
<p>首席执行官</p>
<p>info@shuttlepharma.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/11935/289953_4e6665b074f8d9d6_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="176" height="151" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/11935/289953_4e6665b074f8d9d6_logo.jpg"/></p>
<p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/289953</p>
<p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/289953/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/289953/375"/></p>

医疗业 ETF - Vanguard

2 倍做多纳斯达克生物技术 ETF - ProShares

标普全球医疗股指数 ETF - iShares

<p>Shuttle Pharmaceuticals Holdings, Inc.（纳斯达克代码：SHPH）推出了其 molecule.ai 平台的高级版本，增强了其在治疗发现方面的能力。此次更新引入了用于评估和优先排序治疗候选药物的新模型，整合了预测和生成能力。此外，还推出了一种下一代自主 AI 代理系统，能够在科学工作流程中实现多步骤推理和协调。这一创新旨在缩短药物开发的时间和成本，使 Shuttle Pharma 在 AI 驱动的生物制药创新中处于领先地位</p>

<p>Gaithersburg, Maryland--(Newsfile Corp. - March 26, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) (&#34;Shuttle Pharma&#34; or the &#34;Company&#34;), today announced a major advancement to its <em>molecule.ai</em> platform, significantly expanding its capabilities in therapeutic discovery and positioning the Company at the forefront of AI-driven drug development.</p>
<div class="lb-trans"><p>马里兰州盖瑟斯堡 --（Newsfile Corp. -2026 年 3 月 26 日）- Shuttle Pharmaceuticals Holdings, Inc.（纳斯达克：SHPH）（&#34;Shuttle Pharma&#34;或&#34;公司&#34;）今天宣布其_molecule.ai_平台的重大进展，显著扩展了其在治疗发现方面的能力，并将公司置于基于人工智能的药物开发的前沿。</p>
</div><p>The latest release introduces new models that enable users to more effectively evaluate, prioritize, and advance therapeutic candidates. By integrating enhanced predictive and generative capabilities into a unified platform, Shuttle Pharma is accelerating the transition from fragmented data analysis toward a scalable, end-to-end solution for therapeutic development.</p>
<div class="lb-trans"><p>最新发布引入了新的模型，使用户能够更有效地评估、优先排序和推进治疗候选药物。通过将增强的预测和生成能力整合到一个统一的平台中，Shuttle Pharma 正在加速从碎片化数据分析向可扩展的端到端治疗开发解决方案的过渡。</p>
</div><p>This update marks a critical evolution for AI-driven drug discovery: from standalone model outputs to a more sophisticated reasoning system. The platform can now identify and prioritize relationships between genes and disease pathways and predict compound interactions with specific biological targets. Combined with existing molecular prediction tools, molecule.ai delivers a more connected and efficient framework for evaluating therapeutic opportunities-driving faster, higher-confidence decision-making earlier in the discovery lifecycle.</p>
<div class="lb-trans"><p>此次更新标志着基于人工智能的药物发现的关键演变：从独立模型输出到更复杂的推理系统。该平台现在可以识别和优先考虑基因与疾病通路之间的关系，并预测化合物与特定生物靶点的相互作用。结合现有的分子预测工具，molecule.ai 提供了一个更连贯和高效的框架，用于评估治疗机会，从而在发现生命周期的早期推动更快速、更高信心的决策。</p>
</div><p>In addition, the Company unveiled a preview of its next-generation autonomous AI agent system, built on top of frontier AI models. This system is designed to move beyond traditional single-step predictions by enabling multi-step reasoning and multi-agent orchestration across complex scientific workflows. The agents will be capable of ingesting multimodal data, leveraging integrated tools, and executing discrete research tasks-dramatically reducing manual effort and increasing throughput for research teams.</p>
<div class="lb-trans"><p>此外，公司还展示了其下一代自主人工智能代理系统的预览，该系统建立在前沿人工智能模型之上。该系统旨在超越传统的单步预测，通过在复杂科学工作流程中实现多步推理和多代理协调。代理将能够摄取多模态数据，利用集成工具，并执行离散的研究任务，显著减少人工工作量并提高研究团队的产出。</p>
</div><p>&#34;This release represents a meaningful step toward fully autonomous therapeutic discovery,&#34; said Chris Cooper, Chief Executive Officer of Shuttle Pharma. &#34;We are not just improving model performance-we are redefining how drug development workflows are executed. By integrating reasoning, prediction, and automation into a single platform, molecule.ai has the potential to materially reduce timelines, lower costs, and increase the probability of success across the development pipeline. We believe this positions Shuttle Pharma to play a leading role in the next generation of AI-powered biopharma innovation.&#34;</p>
<div class="lb-trans"><p>&#34;此次发布代表了朝着完全自主治疗发现迈出的重要一步，&#34; Shuttle Pharma 首席执行官 Chris Cooper 表示。&#34;我们不仅在提高模型性能，我们正在重新定义药物开发工作流程的执行方式。通过将推理、预测和自动化整合到一个平台中，molecule.ai 有潜力显著缩短时间表、降低成本，并提高开发管道的成功概率。我们相信这使 Shuttle Pharma 能够在下一代基于人工智能的生物制药创新中发挥领导作用。&#34;</p>
</div><p>As Shuttle Pharma continues to expand molecule.ai's capabilities, the Company remains focused on building a scalable platform that can unlock new therapeutic opportunities, improve development efficiency, and create long-term value for shareholders.</p>
<div class="lb-trans"><p>随着 Shuttle Pharma 继续扩展 molecule.ai 的能力，公司仍然专注于构建一个可扩展的平台，以解锁新的治疗机会，提高开发效率，并为股东创造长期价值。</p>
</div><p><strong>About Shuttle Pharma</strong></p>
<div class="lb-trans"><p><strong>关于 Shuttle Pharma</strong></p>
</div><p>Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) owns a pharmaceutical software artificial intelligence (&#34;AI&#34;) driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai platform helps researchers explore the chemical space more efficiently, evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development.</p>
<div class="lb-trans"><p>Shuttle Pharmaceuticals Holdings, Inc.（纳斯达克：SHPH）拥有一个用于分子发现和早期药物开发的药物软件人工智能（&#34;AI&#34;）驱动平台。通过将现代人工智能技术与结构化科学工作流程相结合，Molecule.ai 平台帮助研究人员更高效地探索化学空间，以更清晰的视角评估分子想法，并在药物开发的最早阶段做出更明智的决策。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示说明</strong></p>
</div><p>Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute &#34;forward-looking statements.&#34; These statements include, but are not limited to, statements concerning the development and future capabilities of the Molecule.ai platform. The words &#34;anticipate,&#34; &#34;believe,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;should,&#34; &#34;target,&#34; &#34;will,&#34; &#34;would&#34; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including our ability to realize the anticipated benefits from the Molecule.ai platform, risks related to the acquisition and retention of future customers and our ability to generate revenue, our ability to fund our future operations, risks regarding our intellectual property, risks regarding our ability to maintain the listing of our common stock on Nasdaq, as well as other factors discussed in Shuttle Pharma's SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharma disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.</p>
<div class="lb-trans"><p>本新闻稿中关于未来期望、计划和前景的声明，以及关于非历史事实事项的任何其他声明，可能构成&#34;前瞻性声明&#34;。这些声明包括但不限于关于 Molecule.ai 平台的发展和未来能力的声明。&#34;预期&#34;、&#34;相信&#34;、&#34;继续&#34;、&#34;可能&#34;、&#34;估计&#34;、&#34;期望&#34;、&#34;打算&#34;、&#34;可能&#34;、&#34;计划&#34;、&#34;潜在&#34;、&#34;预测&#34;、&#34;项目&#34;、&#34;应该&#34;、&#34;目标&#34;、&#34;将&#34;、&#34;会&#34;及类似表达旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果有实质性差异，包括我们实现 Molecule.ai 平台预期收益的能力、与未来客户的获取和保留相关的风险、我们产生收入的能力、我们资助未来运营的能力、与我们的知识产权相关的风险、我们维持普通股在纳斯达克上市的能力的风险，以及 Shuttle Pharma 在 SEC 备案中讨论的其他因素。本新闻稿中包含的任何前瞻性声明仅在本日期有效，除非联邦证券法要求，否则 Shuttle Pharma 不承担更新任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。</p>
</div><p><strong>Shuttle Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>Shuttle Pharmaceuticals</strong></p>
</div><p>Chris Cooper</p>
<div class="lb-trans"><p>Chris Cooper</p>
</div><p>Chief Executive Officer</p>
<div class="lb-trans"><p>首席执行官</p>
</div><p>info@shuttlepharma.com</p>
<div class="lb-trans"><p>info@shuttlepharma.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/11935/289953_4e6665b074f8d9d6_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/11935/289953_4e6665b074f8d9d6_logo.jpg"/></p>
<p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289953</p>
<div class="lb-trans"><p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/289953</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/289953/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/289953/375"/></p>

Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows | SHPH Stock News

StockTitan

标普生物技术 3 倍做多 - Direxion

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

基因改革 ETF - ARK

Shuttle Pharmaceuticals

纳斯达克生物科技指数 ETF - iShares Nasdaq

美国制药 ETF - iShares

医药突破 ETF - ALPS

医疗业 ETF - SPDR

生物科技 ETF - VanEck Vectors

Shuttle Pharmaceuticals 推出用于科学工作流程的自主自我推理 AI 代理 | SHPH 股票新闻